Goodman Advisory Group’s Pfizer PFE Stock Holding History

Goodman Advisory Group’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-614	Closed	-$17.2K	–	142
2026 Q1	$17.2K	Hold	614	–	–	﹤0.01%	137
2025 Q4	$15.3K	Hold	614	–	–	﹤0.01%	133
2025 Q3	$15.6K	Hold	614	–	–	﹤0.01%	136
2025 Q2	$14.9K	Hold	614	–	–	0.01%	112
2025 Q1	$15.6K	Buy	+614	New	+$16.1K	﹤0.01%	141
2024 Q4	–	Sell	-614	Closed	-$17.8K	–	143
2024 Q3	$17.8K	Hold	614	–	–	0.01%	149
2024 Q2	$17.2K	Hold	614	–	–	0.01%	144
2024 Q1	$17K	Hold	614	–	–	0.01%	123
2023 Q4	$17.7K	Sell	614 -25,240	-98%	-$763K	0.01%	112
2023 Q3	$858K	Sell	25,854 -228,592	-90%	-$8.08M	0.32%	50
2023 Q2	$9.33M	Buy	254,446 +253,832	+41,341%	+$9.88M	3.46%	6
2023 Q1	$25.1K	Hold	614	–	–	0.01%	93
2022 Q4	$31K	Hold	614	–	–	0.02%	86
2022 Q3	$27K	Hold	614	–	–	0.01%	89
2022 Q2	$32K	Buy	+614	New	+$31.3K	0.01%	88

Other funds holding PFE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Goodman Advisory Group's PFE Position: Q2 2026 in Review

Goodman Advisory Group sold out of Pfizer (PFE) in Q2 2026, closing a stake of 614 shares — an estimated $17.2K sold.

Goodman Advisory Group first reported a position in PFE in Q2 2022 and held it in 15 quarters. The position peaked at $9.33M in Q2 2023. 2,827 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

Goodman Advisory Group reported no remaining Pfizer position as of Q2 2026 after selling out during the quarter.
Goodman Advisory Group sold 614 Pfizer shares in Q2 2026, an estimated $17.2K.
Goodman Advisory Group first reported a position in Pfizer in Q2 2022 and held it in 15 quarters.
Goodman Advisory Group's Pfizer position peaked at $9.33M in Q2 2023.
2,827 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Goodman Advisory Group's 13F filing for Q2 2026, filed 12 Aug 2026.